Brief: AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
09/07/2024 13:20
July 9 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA ANNOUNCES STRATEGIC REPRIORITIZATION TO
PURSUE A
BIOSIMILAR PATHWAY FOR ABP-450
* AEON BIOPHARMA- PLAN TO MOVE AHEAD WITH HEAD-TO-HEAD
COMPARISON
TO BOTOX IN CERVICAL DYSTONIA PHASE 3 STUDY VIA 351(K) PATHWAY
POST FDA MEETING IN Q3
Source text for Eikon: ID:nGNX3ym7j5
Further company coverage: AEON.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition